News
IPHYF
2.250
NaN%
--
Innate Therapeutics: Buy Reiterated on Broad IPH4502 Responses; $7 Price Target Unchanged
TipRanks · 10h ago
Innate Pharma Reports Initial Phase 1 Data for IPH4502 at ENA 2026
TipRanks · 16h ago
Innate Pharma presents initial IPH4502 study data
TipRanks · 17h ago
Innate Pharma Announces November 18 IPH4502 Phase 1 Data Event
TipRanks · 6d ago
Innate Pharma to Host IPH4502 Phase 1 Data Event
TipRanks · 11/11 08:20
Buy Rating Reaffirmed as IPH4502, PACIFIC-9, and Lacutamab Catalysts Support Unchanged $9 Price Target
TipRanks · 11/06 14:04
Innate Pharma Reports Stronger Cash Position and Pipeline Progress
TipRanks · 11/05 07:47
Innate Pharma announces AstraZeneca updated timing for PACIFIC-9 data readout
TipRanks · 10/27 09:35
AstraZeneca Pushes Back PACIFIC-9 Lung Cancer Trial Readout, Extending Timeline for Innate Pharma’s Monalizumab
TipRanks · 10/27 07:21
Innate Pharma to Highlight Cancer Immunotherapy Pipeline at November Investor Conferences
TipRanks · 10/21 05:40
Innate Pharma to Host Q3 2026 Business Update Call
TipRanks · 10/20 05:37
H.C. Wainwright Remains a Buy on Innate Pharma (IPHA)
TipRanks · 10/01 14:36
Innate Pharma Maps Pivotal Path in Earnings Call
TipRanks · 09/23 00:03
BTIG Remains a Buy on Innate Pharma (IPHA)
TipRanks · 09/18 10:55
Innate Pharma Secures Sobi Partnership Cash and Extends Runway as Key Oncology Trials Advance
TipRanks · 09/17 05:42
Innate Pharma-Sobi Partnership Closes, Unlocks $75 Million and Phase 3 Lacutamab Trial
TipRanks · 09/16 20:40
Innate Pharma says previously announced partnership with Sobi now effective
TipRanks · 09/16 20:05
Innate Pharma to deliver H1 2026 business update via investor webcast
TipRanks · 09/10 05:37
Innate Pharma to Highlight Oncology Pipeline at H.C. Wainwright Investment Conference
TipRanks · 09/02 07:08
Innate Pharma to Spotlight Oncology Pipeline at H.C. Wainwright Investor Conference
TipRanks · 09/02 05:40
More
Webull provides a variety of real-time IPHYF stock news. You can receive the latest news about Innate Pharma Marseille through multiple platforms. This information may help you make smarter investment decisions.
About IPHYF
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.